To the Editor In a JAMA Clinical Evidence Synopsis article, Dr Schuetz and colleagues1 summarized their recent Cochrane review2 of outcomes associated with procalcitonin-guided antibiotic treatment of patients with acute upper and lower respiratory tract infections vs usual care. The article is confusing in that it does not address why there would be an associated survival benefit, especially when no such association has been found for its use to manage patients with sepsis.3
Talan DA. Procalcitonin to Guide Antibiotic Decisions. JAMA. 2018;320(4):406. doi:10.1001/jama.2018.6713
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: